← Leaderboards
Therese Bittermann
University Of Pennsylvania
$2,559,387
Attributed
$2,963,370
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $822.7K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,963,370 · 3
By mechanism
R01$2,031,076 · 2
K08$932,294 · 1
Top collaborators
- Marina Serper2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Elizabeth A Heller$8,280,996
- Edna B Foa$22,552,226
- Marina Serper$7,301,871
- David A Mankoff$17,196,499
- Richard C. Crist$940,547
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposSafetyFutureTransplant RecipientsMalignant NeoplasmsLiver TransplantationEvaluationPreventTransplantationConsensusCaringClinical TrialsMedicareUnited Network For Organ SharingResourcesPost-TransplantEffectivenessImmunosuppressionMedicare ClaimOrganLiver DiseasesLifeLiverLiver Failure
Grant awards (11)
Impact of mammalian target of rapamycin inhibitor therapy on aging-related outcomes$397,093
R01 · FY2025 · AG · contact PI
Impact of mammalian target of rapamycin inhibitor therapy on aging-related outcomes$409,578
R01 · FY2024 · AG · contact PI
2/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)$401,716
R01 · FY2024 · AA
Impact of mammalian target of rapamycin inhibitor therapy on aging-related outcomes$416,439
R01 · FY2023 · AG · contact PI
2/4-American Consortium of Early Liver Transplantation-Prospective Alcohol-associated liver disease Cohort Evaluation (ACCELERATE-PACE)$406,250
R01 · FY2023 · AA
Impact of immunosuppression variability on outcomes after liver transplantation$169,236
K08 · FY2022 · DK · contact PI
Impact of immunosuppression variability on outcomes after liver transplantation$84,614
K08 · FY2022 · DK · contact PI
Impact of immunosuppression variability on outcomes after liver transplantation$169,236
K08 · FY2021 · DK · contact PI
Impact of immunosuppression variability on outcomes after liver transplantation$169,236
K08 · FY2020 · DK · contact PI
Impact of immunosuppression variability on outcomes after liver transplantation$169,236
K08 · FY2019 · DK · contact PI
Impact of immunosuppression variability on outcomes after liver transplantation$170,736
K08 · FY2018 · DK · contact PI